BB Biotech Valuation
| BION Stock | CHF 37.30 0.15 0.40% |
At this time, the entity appears to be fairly valued. BB Biotech AG owns a latest Real Value of ₣37.54 per share. The recent price of the entity is ₣37.3. Our model approximates the value of BB Biotech AG from evaluating the entity fundamentals such as Return On Asset of -0.0411, shares owned by insiders of 1.70 %, and Shares Owned By Institutions of 7.82 % as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that BB Biotech's price fluctuation is very steady at this time. Calculation of the real value of BB Biotech AG is based on 3 months time horizon. Increasing BB Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BION stock is determined by what a typical buyer is willing to pay for full or partial control of BB Biotech AG. Since BB Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BION Stock. However, BB Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 37.3 | Real 37.54 | Hype 37.3 |
The intrinsic value of BB Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BB Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BB Biotech AG helps investors to forecast how BION stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BB Biotech more accurately as focusing exclusively on BB Biotech's fundamentals will not take into account other important factors: BB Biotech Total Value Analysis
BB Biotech AG is currently anticipated to have takeover price of 509.23 M with market capitalization of 3.15 B, debt of 0, and cash on hands of 2.83 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BB Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
509.23 M | 3.15 B | 0 | 2.83 M |
BB Biotech Investor Information
The company has price-to-book (P/B) ratio of 1.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. BB Biotech AG recorded a loss per share of 16.73. The entity last dividend was issued on the 27th of March 2023. The firm had 5:1 split on the 29th of March 2016. Based on the key indicators obtained from BB Biotech's historical financial statements, BB Biotech AG is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.BB Biotech Asset Utilization
One of the ways to look at asset utilization of BION is to check how much profit was generated for every dollar of assets it reports. BB Biotech AG owns a negative utilization of current and long term assets of -0.0411 %, losing ₣4.11E-4 for each franc of current and long term assets held by the entity. Discouraging asset utilization signifies that the company is being less competent with each franc of current and long term assets it owns. Strictly speaking, asset utilization of BB Biotech AG shows how wasteful it operates for each franc spent on its current and long term assets.BB Biotech Ownership Allocation
BB Biotech AG secures a total of 54.99 Million outstanding shares. Roughly 90.48 % of BB Biotech outstanding shares are held by general public with 1.7 percent owned by insiders and only 7.82 (percent) by institutions. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.BB Biotech Profitability Analysis
Net Loss for the year was (404.81 M) with profit before overhead, payroll, taxes, and interest of 4 K.About BB Biotech Valuation
Our relative valuation model uses a comparative analysis of BB Biotech. We calculate exposure to BB Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BB Biotech's related companies.BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland. BB BIOTECH operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange.
8 Steps to conduct BB Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BB Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BB Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BB Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BB Biotech's revenue streams: Identify BB Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BB Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BB Biotech's growth potential: Evaluate BB Biotech's management, business model, and growth potential.
- Determine BB Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BB Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.